

CITATION REPORT

List of articles citing

Precursor lesions of ovarian epithelial malignancy

DOI: 10.1046/j.1365-2559.2001.01042.x
Histopathology, 2001, 38, 87-95.

Source: <https://exaly.com/paper-pdf/32977674/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
270	Molecular targets for epithelial ovarian cancer. 606-618		
269	Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. 2001 , 98, 15209-14		70
268	Non-neoplastic diseases of the ovary: selected topics. 2002 , 8, 172-182		1
267	Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. 2002 , 1, 53-62		289
266	Changes in the mouse ovarian surface epithelium with age and ovulation number. 2002 , 191, 105-11		27
265	Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. 2002 , 98, 895-9		50
264	Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. 2002 , 102, 398-406		114
263	Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. 2002 , 94, 2380-92		62
262	Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. 2002 , 95, 1802-15		46
261	Epithelial abnormalities in cystic ovarian endometriosis. 2002 , 84, 280-4		75
260	The dominance of the microenvironment in breast and ovarian cancer. 2002 , 12, 97-104		102
259	Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. 2003 , 91, 15-31		52
258	Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. 2003 , 98, 2607-23		50
257	Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. <i>Histopathology</i> , 2003 , 43, 26-32	7.3	31
256	Lack of proliferative activity of surface epithelial inclusion cysts of the ovary. 2003 , 13, 303-7		12
255	Translational research in ovarian cancer: a must. 2003 , 13 Suppl 2, 220-30		5
254	Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. 2003 , 22, 4243-56		29

253	K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. 2003 , 83, 251-8	36
252	Loss of cables, a novel gene on chromosome 18q, in ovarian cancer. 2003 , 16, 863-8	20
251	The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. 2003 , 1, 72	31
250	Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. 2003 , 163, 2503-12	264
249	Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. 2003 , 162, 1603-10	53
248	Metaplastic potential of p53 down-regulation in ovarian surface epithelial cells affected by ovulation. 2003 , 191, 75-81	11
247	Abdominal pain during pregnancy. 2003 , 32, 1-58	105
246	Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations. 2003 , 22, 109-20	45
245	. 2003 , 15, 321-326	7
244	Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. 2003 , 22, 374-7	99
243	Ovarian endometriosis: from pathogenesis to surgical treatment. 2003 , 15, 321-6	76
242	Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells. 2003 , 228, 308-14	25
241	Potential for TRAIL as a therapeutic agent in ovarian cancer. 2004 , 67, 347-64	9
240	Epigenetic inactivation of TMS1/ASC in ovarian cancer. 2004 , 10, 2000-6	76
239	WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. <i>Histopathology</i> , 2004 , 44, 109-15	7-3 204
238	Malignant mixed mullerian tumour of the fallopian tube occurring in a patient with Peutz-Jegher syndrome. 2004 , 44, 77-9	7
237	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. 2004 , 23, 8171-83	69
236	Molecular genetic analysis of ovarian serous cystadenomas. 2004 , 84, 778-84	40

235	Focus on epithelial ovarian cancer. 2004 , 5, 19-24	241
234	Cyclooxygenase-2 expression in borderline ovarian tumors. 2004 , 95, 46-51	9
233	Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. 2004 , 191, 718-32	96
232	Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. 2004 , 3, 265-81	28
231	Diagnostic and molecular genetic pathology of serous borderline tumours of the ovary. 2004 , 10, 318-325	3
230	Current challenges and opportunities for research on borderline ovarian tumors. 2004 , 35, 961-70	36
229	Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation. 2004 , 23, 316-20	29
228	Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. 2004 , 229, 546-52	84
227	K-Ras Mutations in Serous Borderline Tumors of the Ovary. 2005 , 4, 357-361	
226	Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. 2005 , 11, 2123-31	37
225	Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. 2005 , 29, 218-24	336
224	An Immunohistochemical Comparison Between Low-Grade and High-Grade Ovarian Serous Carcinomas. 2005 , 29, 1034-1041	140
223	Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study. 2005 , 192, 48-54	56
222	Emerging issues of the expression profiling technologies for the study of gynecologic cancer. 2005 , 193, 908-18	9
221	Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. 2005 , 15, 878-83	56
220	Serous borderline tumours of the ovary. <i>Histopathology</i> , 2005 , 47, 310-5	73 49
219	Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. 2005 , 11, 531-7	233
218	Ovarian cancer metastasis: integrating insights from disparate model organisms. 2005 , 5, 355-66	427

217	Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. 2005 , 99, 367-75	10
216	Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer. 2005 , 99, 664-70	31
215	Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. 2005 , 113, 372-8	91
214	Centrosome abnormalities in ovarian cancer. 2005 , 113, 746-51	37
213	Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. 2005 , 92, 337-43	22
212	Location of inclusion cysts in mouse ovaries in relation to age, pregnancy, and total ovulation number: implications for ovarian cancer?. 2005 , 205, 483-90	28
211	Microarray comparative genomic hybridization profile of a murine model for epithelial ovarian cancer reveals genomic imbalances resembling human ovarian carcinomas. 2005 , 26, 236-44	18
210	Differential expression of laminin isoforms in ovarian epithelial carcinomas suggesting different origin and providing tools for differential diagnosis. 2005 , 53, 1293-300	17
209	Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. 2005 , 65, 3726-34	40
208	Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. 2005 , 11, 6422-30	311
207	Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. 2005 , 11, 7273-9	113
206	Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. <i>Women's Oncology Review</i> , 2005 , 5, 219-221	
205	Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. 2005 , 11, 6116-26	250
204	Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. 2005 , 65, 2162-9	399
203	Ovarian cancer, the coagulation pathway, and inflammation. 2005 , 3, 25	90
202	Carcinogenic potential of ovulatory genotoxicity. 2005 , 73, 586-90	33
201	Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. 2006 , 169, 258-67	25
200	Histopathological challenges in assessing borderline ovarian tumours. 2006 , 12, 325-346	3

199	The role of gene expression profiling in the clinical management of ovarian cancer. 2006 , 42, 2930-8	18
198	Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. 2006 , 247, 4-21	139
197	Gene expression data analysis in subtypes of ovarian cancer using covariance analysis. 2006 , 4, 999-1014	4
196	Magnetic resonance imaging of adnexal masses. 2006 , 17, 379-97	13
195	Immunohistochemical and functional biomarkers of value in female genital tract lesions. 2006 , 25, 101-20	50
194	Classifications of ovarian cancer tissues by proteomic patterns. 2006 , 6, 5846-56	37
193	Irregularly shaped inclusion cysts display increased expression of Ki67, Fas, Fas ligand, and procaspase-3 but relatively little active caspase-3. 2006 , 16, 231-9	9
192	Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma. 2006 , 19, 1615-23	28
191	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 2006 , 103, 405-16	90
190	Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma?. 2006 , 56, 233-9	18
189	A distinct molecular profile associated with mucinous epithelial ovarian cancer. 2006 , 94, 904-13	87
188	Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. 2007 , 6, 11	92
187	A system-wide analysis of differentially expressed genes in ectopic and eutopic endometrium. 2007 , 22, 2093-102	38
186	CA125 in ovarian cancer. 2007 , 1, 513-23	115
185	HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. 2007 , 14, 605-14	24
184	The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. 2007 , 9, 1-12	30
183	Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. 2007 , 31, 999-1006	53
182	Small cell carcinoma of pulmonary type inside a microinvasive mucinous cystadenocarcinoma of the ovary: a case report. 2007 , 26, 426-31	18

181	Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. 2007 , 247, 130-6	45
180	Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. 2007 , 255, 263-74	53
179	MicroRNA signatures in human ovarian cancer. 2007 , 67, 8699-707	1251
178	Large-scale proteomics analysis of human ovarian cancer for biomarkers. 2007 , 6, 1440-50	70
177	Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. 2007 , 46, 130-43	27
176	High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. <i>Histopathology</i> , 2007 , 50, 773-9	73 80
175	Atypical mucinous metaplasia and intraepithelial neoplasia of the female genital tract—a case report and review of the literature. 2007 , 17, 1147-50	15
174	Overexpression of mammaglobin B in epithelial ovarian carcinomas. 2007 , 105, 578-85	26
173	Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma. 2007 , 106, 201-6	17
172	A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. 2007 , 321, 86-93	24
171	Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1alpha and the PI3K pathway. 2008 , 105, 1194-201	26
170	Genomic analysis of epithelial ovarian cancer. 2008 , 18, 538-48	55
169	Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. 2008 , 21, 676-84	82
168	The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. 2008 , 76, 193-205	40
167	Germ cell specific protein VASA is over-expressed in epithelial ovarian cancer and disrupts DNA damage-induced G2 checkpoint. 2008 , 111, 312-9	31
166	Whole-Genome Expression Profiling of Papillary Serous Ovarian Cancer: Activated Pathways, Potential Targets, and Noise. 2008 , 149-164	
165	[Ovarian epithelial dysplasia: myth or reality? Review]. 2008 , 36, 800-7	7
164	Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. 2008 , 9, 1076-85	82

163	Analysis of gene expression in early-stage ovarian cancer. 2008 , 14, 7850-60	36
162	Early detection of ovarian cancer. 2008 , 2, 291-303	57
161	Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. 2008 , 27, 151-60	329
160	WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. 2008 , 40, 592-9	17
159	Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. 2008 , 31, 693-703	20
158	Molecular Pathogenesis of Epithelial Ovarian Cancer. 2008 , 441-454	1
157	Expression of the Epidermal Growth Factor Receptor Family in Correlation to the Estrogen Receptor Expression in Peritoneal and Ovarian Endometriosis. 2009 , 1, 122-130	
156	The Expression and Significance of Dickkopf-1 in Epithelial Ovarian Carcinoma. 2009 , 24, 165-170	13
155	Genetically engineered mouse models of ovarian cancer and their utility in drug discovery. 2009 , Chapter 14, Unit14.11	3
154	Translational control during early development. 2009 , 90, 211-54	15
153	Possible angiogenic roles for claudin-4 in ovarian cancer. 2009 , 8, 1806-14	30
152	Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. 2009 , 114, 32-6	15
151	Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. 2009 , 22, 197-205	67
150	The biology of ovarian cancer: new opportunities for translation. 2009 , 9, 415-28	1024
149	The mammalian ovary from genesis to revelation. 2009 , 30, 624-712	480
148	Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. 2009 , 40, 965-74	37
147	Ovarian cancer. 2009 , 4, 287-313	505
146	Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. 2009 , 11, 529-41	30

145	The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. 2009 , 19, 471-9		52
144	miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. 2009 , 19, 641-7		48
143	Endometriosis and Cancer. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2010 , 32, S26-S28	1.3	
142	Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary. 2010 , 18, 509-11		2
141	Endometriosis: Diagnosis and Management. 2010 , 2, 107-134		6
140	Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. 2010 , 136, 771-8		21
139	The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer. 2010 , 117, 460-6		28
138	Ovarian serous low malignant potential (borderline) tumor--does "micropapillary" matter?. 2010 , 117, 1-3		7
137	Molecular characterization of ovarian cancer by gene-expression profiling. 2010 , 118, 88-92		37
136	Development of a syngeneic mouse model of epithelial ovarian cancer. 2010 , 3, 24		40
135	Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. <i>Journal of Oncology</i> , 2010 , 2010, 568938	4.5	89
134	Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. <i>PLoS ONE</i> , 2010 , 5, e10471	3.7	42
133	Individual Cell-Based Model for In-Vitro Mesothelial Invasion of Ovarian Cancer. 2010 , 5, 203-223		27
132	AXL is an essential factor and therapeutic target for metastatic ovarian cancer. 2010 , 70, 7570-9		160
131	Human steroidogenic factor-1 (hSF-1) regulates progesterone biosynthesis and growth of ovarian surface epithelial cancer cells. 2010 , 119, 14-25		9
130	The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. 2010 , 317, 112-9		17
129	Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. 2010 , 42, 1262-72		57
128	Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management. 2010 , 26, 631-43		18

127	[Ovarian carcinogenesis: recent and past hypotheses]. 2011 , 39, 216-23		2
126	Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. <i>PLoS ONE</i> , 2011 , 6, e20705	3-7	23
125	Fallopian tube correlates of ovarian serous borderline tumors. 2011 , 35, 1759-65		51
124	The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation. 2011 , 11, 405		44
123	Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. 2011 , 10, 125		35
122	Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. 2011 , 11, 4677-87		32
121	Protein expression patterns associated with advanced stage ovarian cancer. 2011 , 32, 1992-2003		20
120	Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. 2011 , 31, 625-46		121
119	Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. 2011 , 108, 1104-9		47
118	Genomic complexity and AKT dependence in serous ovarian cancer. 2012 , 2, 56-67		89
117	Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. 2012 , 31, 2512-20		64
116	Evaluation of microsatellite instability in women with epithelial ovarian cancer. 2012 , 4, 556-560		13
115	Expression and role of the inhibitor of apoptosis protein livin in chemotherapy sensitivity of ovarian carcinoma. 2012 , 41, 1021-8		10
114	Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. 2012 , 14, 994-1004		82
113	Technical challenges and limitations of current mouse models of ovarian cancer. 2012 , 5, 39		21
112	Primary cilia and aberrant cell signaling in epithelial ovarian cancer. 2012 , 1, 15		50
111	Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines. 2012 , 138, 323-38		18
110	Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. <i>Cancer Science</i> , 2012 , 103, 747-55	6.9	40

109	Increased expression of OCIA domain containing 2 during stepwise progression of ovarian mucinous tumor. 2012 , 62, 471-6		8
108	High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker. 2013 , 18, 18		8
107	Ovarian cancer: genomic analysis. 2013 , 24 Suppl 10, x7-15		23
106	Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis. 2013 , 6, 92		13
105	Thrombomodulin mediates the progression of epithelial ovarian cancer cells. 2013 , 34, 3743-51		9
104	Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. <i>Histopathology</i> , 2013 , 62, 44-58	7.3	190
103	Revisiting ovarian cancer preclinical models: implications for a better management of the disease. 2013 , 39, 561-8		21
102	Estrogen and androgen receptor expression in surface epithelium and inclusion cyst in the ovary of premenopausal and postmenopausal women. 2013 , 6, 85		3
101	STUDY OF OVARIAN CHANGES IN RATS WITH MAMMARY CARCINOMAS. 2013 , 25-32		
100	Precursors and pathogenesis of ovarian carcinoma. 2013 , 45, 229-42		93
99	Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis. 2013 , 110, 8140-5		31
98	Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 13687-703	6.3	25
97	Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. <i>PLoS ONE</i> , 2013 , 8, e55362	3.7	29
96	The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. 2013 , 3, 153		78
95	Ovarian Cancer Biomarkers. 2014 , 25-77		19
94	Recent concepts of ovarian carcinogenesis: type I and type II. 2014 , 2014, 934261		119
93	Development of a mouse model of menopausal ovarian cancer. 2014 , 4, 36		11
92	Coxsackievirus B3 infection reduces female mouse fertility. 2015 , 64, 343-52		1

91	Apatone \square induces endometrioid ovarian carcinoma (MDAH 2774) cells to undergo karyolysis and cell death by autoschizis: A potent and safe anticancer treatment. 2015 , 1, 25-39	4
90	Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. 2015 , 8, 29	39
89	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. 2015 , 39, 1548-57	50
88	An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer: A Feasibility Study. 2015 , 25, 985-92	28
87	Structural perspective of ARHI mediated inhibition of STAT3 signaling: an insight into the inactive to active transition of ARHI and its interaction with STAT3 and importin \square 2015 , 27, 739-55	20
86	Genome-wide significant risk associations for mucinous ovarian carcinoma. 2015 , 47, 888-97	60
85	Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. 2015 , 14, 29	13
84	Primary peritoneal clear cell carcinoma versus ovarian carcinoma versus malignant transformation of endometriosis: a vexing issue. 2015 , 23, 211-6	9
83	Quantifying physical activity and the associated barriers for women with ovarian cancer. 2015 , 25, 577-83	24
82	Do hereditary syndrome-related gynecologic cancers have any specific features?. 2015 , 6, 545-52	6
81	Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. 2015 , 149, R59-70	53
80	Aqueous Extract of Paris polyphylla (AEPP) Inhibits Ovarian Cancer via Suppression of Peroxisome Proliferator-Activated Receptor-Gamma Coactivator (PGC)-1alpha. 2016 , 21,	15
79	Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes. 2016 , 9, 189-99	19
78	HNF1 \square drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). 2016 , 37, 4813-29	34
77	KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice. 2017 , 140, 1860-1869	19
76	Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. 2017 , 388, 158-166	8
75	miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. 2017 , 70, 98-104	12
74	Do some epithelial ovarian cancers originate from a fallopian tube ciliate cell lineage?. 2017 , 107, 16-21	4

73	Dickkopf-4 is frequently overexpressed in epithelial ovarian carcinoma and promotes tumor invasion. 2017 , 17, 455		8
72	Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube. 2017 , 17, 422		7
71	Developing a deeper insight into reproductive biomarkers. 2017 , 44, 159-170		5
70	Systematic module approach identifies altered genes and pathways in four types of ovarian cancer. <i>Molecular Medicine Reports</i> , 2017 , 16, 7907-7914	2.9	2
69	Subtypes of Ovarian Cancer and Ovarian Cancer Screening. <i>Diagnostics</i> , 2017 , 7,	3.8	48
68	The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	44
67	The Role of Endocrine G Protein-Coupled Receptors in Ovarian Cancer Progression. <i>Frontiers in Endocrinology</i> , 2017 , 8, 66	5.7	16
66	Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. <i>Pharmacology & Therapeutics</i> , 2018 , 186, 1-24	13.9	159
65	miRNAs and ovarian cancer: An overview. <i>Journal of Cellular Physiology</i> , 2018 , 233, 3846-3854	7	102
64	Cell Origins of High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2018 , 10,	6.6	87
63	The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. 2018 , 865-948		1
62	Recent Insights into Mucinous Ovarian Carcinoma. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	31
61	In vivo selection reveals autophagy promotes adaptation of metastatic ovarian cancer cells to abdominal microenvironment. <i>Cancer Science</i> , 2019 , 110, 3204-3214	6.9	7
60	Identification of a Prognostic Signature Associated With DNA Repair Genes in Ovarian Cancer. <i>Frontiers in Genetics</i> , 2019 , 10, 839	4.5	14
59	Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. <i>Journal of Biotechnology</i> , 2019 , 297, 58-65	3.7	23
58	A Comprehensive Review of Ovarian Serous Carcinoma. <i>Advances in Anatomic Pathology</i> , 2019 , 26, 329-339		18
57	. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019 , 41 Suppl 1, S164-S166	1.3	
56	Histotype-specific analysis of acid ceramidase expression in ovarian cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 476, 855-862	5.1	2

55	A descriptive study of the clinico-pathological and surgical characteristics of patients with primary epithelial ovarian cancer. A cross sectional study. <i>Annals of Medicine and Surgery</i> , 2020 , 59, 254-257	2	
54	Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation. <i>Cell Reports</i> , 2020 , 32, 108086	10.6	6
53	Human spermbots for patient-representative 3D ovarian cancer cell treatment. <i>Nanoscale</i> , 2020 , 12, 20467-20481	7.7	8
52	MicroRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges. <i>DNA and Cell Biology</i> , 2020 ,	3.6	1
51	miR-454 suppresses the proliferation and invasion of ovarian cancer by targeting E2F6. <i>Cancer Cell International</i> , 2020 , 20, 237	6.4	8
50	EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance. <i>Cell Adhesion and Migration</i> , 2020 , 14, 57-68	3.2	5
49	Histopathological Variants of Ovarian Tumors and Their Presentation in Rural Tertiary Care Center of Northern India: An Observational Study. <i>Indian Journal of Gynecologic Oncology</i> , 2020 , 18, 1	0.2	1
48	ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo. <i>Experimental Cell Research</i> , 2020 , 392, 112009	4.2	5
47	Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	10
46	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. <i>IScience</i> , 2021 , 24, 102757	6.1	3
45	Ovarian cysts and granulosa cell tumors develop after sublethal total body irradiation in mice.		
44	Ovarian Cancer.		2
43	Animal models of ovarian cancer. <i>Cancer Treatment and Research</i> , 2009 , 149, 353-91	3.5	13
42	The blood-follicle barrier (BFB) in disease and in ovarian function. <i>Advances in Experimental Medicine and Biology</i> , 2012 , 763, 186-92	3.6	38
41	Molecular Pathogenesis of Ovarian Cancer: An Inextricable Maze. 2018 , 123-134		1
40	Female reproductive system. 2011 , 1399-1657		1
39	Epidemiology of Ovarian, Fallopian Tube, and Primary Peritoneal Cancers. 2004 , 326-340		2
38	Immunohistochemical and functional biomarkers of value in female genital tract lesions. 2009 , 999-1014		2

37	Peritoneum and retroperitoneum. 2007 , 279-296		1
36	Ovarian Cancer. 2006 , 1013-1026		19
35	Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. <i>PLoS ONE</i> , 2009 , 4, e6454	3-7	43
34	Conditional inactivation of p53 in mouse ovarian surface epithelium does not alter MIS driven Smad2-dominant negative epithelium-lined inclusion cysts or teratomas. <i>PLoS ONE</i> , 2013 , 8, e65067	3-7	15
33	Type-specific cell line models for type-specific ovarian cancer research. <i>PLoS ONE</i> , 2013 , 8, e72162	3-7	161
32	Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma. <i>Oncotarget</i> , 2016 , 7, 66077-66086	3-3	11
31	Antimetastatic effects of cordycepin mediated by the inhibition of mitochondrial activity and estrogen-related receptor β in human ovarian carcinoma cells. <i>Oncotarget</i> , 2017 , 8, 3049-3058	3-3	27
30	The inhibition of cordycepin on cancer stemness in TGF-beta induced chemo-resistant ovarian cancer cell. <i>Oncotarget</i> , 2017 , 8, 111912-111921	3-3	9
29	Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells. <i>Oncotarget</i> , 2011 , 2, 477-84	3-3	13
28	Metabolic alterations caused by HNF1 α expression in ovarian clear cell carcinoma contribute to cell survival. <i>Oncotarget</i> , 2015 , 6, 26002-17	3-3	34
27	Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation and collective cell movement in ovarian cancer cells. <i>Oncotarget</i> , 2016 , 7, 4110-21	3-3	24
26	Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells. <i>Oncotarget</i> , 2016 , 7, 11397-411	3-3	22
25	Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020 , 20, 1530-1537	2.2	10
24	Pathology of BRCA-Associated Ovarian Cancers, Including Occult Cancers. 2008 , 29-43		2
23	Global epidemiology, risk factors, and histological types of ovarian cancers in Trinidad. <i>Journal of Family Medicine and Primary Care</i> , 2019 , 8, 1058-1064	1.5	6
22	Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2008 , 132, 1753-60	5	107
21	MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer. <i>Journal of Oncology</i> , 2021 , 2021, 3408937	4-5	2
20	Früherkennung, Vorsorge und Prophylaxe. 2009 , 59-69		

19	The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. 2011 , 818-895		2
18	Proliferative and angiogenic activity of endometriomas. <i>Russian Journal of Human Reproduction</i> , 2016 , 22, 91	0.3	2
17	Most commonly mutated genes in High Grade Serous Ovarian Carcinoma are nonessential for ovarian surface epithelial stem cell transformation.		1
16	Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. <i>Women's Oncology Review</i> , 2005 , 5, 219-221		
15	Epithelial Ovarian Cancer. 2005 , 473-486		
14	Pathology of Incipient Neoplasia. 2005 , 69-96		
13	Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific. <i>International Journal of Clinical and Experimental Pathology</i> , 2008 , 1, 502-9	1.4	17
12	Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. <i>International Journal of Clinical and Experimental Pathology</i> , 2012 , 5, 182-6	1.4	11
11	Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes.. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022 , 1877, 188681	11.2	0
10	Table_1.docx. 2019 ,		
9	Table_2.docx. 2019 ,		
8	Table_3.docx. 2019 ,		
7	Table_4.docx. 2019 ,		
6	Table_5.docx. 2019 ,		
5	Table_6.docx. 2019 ,		
4	Table_7.docx. 2019 ,		
3	Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses. 2005 , 14, 98-107		79
2	Peritoneal and Subperitoneal Stroma May Facilitate Regional Spread of Ovarian Cancer. 2005 , 11, 113-122		22

1 Ovarian Cancer Pathology. **2022**, 57-85

o